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Abstract 1 
Background: Cigarette smoking increases the risk of multiple diseases including cancers, 2 
osteoporosis, lung, and cardiovascular disorders. DNA methylation leaves a long-term 3 
signature of smoking exposure and is one potential mechanism by which tobacco exposure 4 
predisposes to these adverse health outcomes. 5 
Methods and Results: To comprehensively determine the association between cigarette 6 
smoking and DNA methylation, we conducted a meta-analysis of genome-wide DNA 7 
methylation assessed using the Illumina BeadChip 450K array on 15,907 blood derived 8 
DNA samples from participants in 16 cohorts (including 2,433 current, 6,518 former, and 9 
6,956 never smokers). Comparing current versus never smokers, 2,623 CpG sites (CpGs), 10 
annotated to 1,405 genes, were statistically significantly differentially methylated at 11 
Bonferroni threshold of p<1x10-7. Genes annotated to these CpGs were enriched for 12 
associations with several smoking-related traits in genome-wide studies including 13 
pulmonary function, cancers, inflammatory diseases and heart disease. Comparing former 14 
versus never smokers, 185 of the CpGs that differed between current and never smokers 15 
were significant (p<1x10-7), indicating a pattern of persistent altered methylation, with 16 
attenuation, after smoking cessation. Transcriptomic integration identified effects on gene 17 
expression at many differentially methylated CpGs. 18 
Conclusions: Cigarette smoking has a broad impact on genome-wide methylation that, at 19 
many loci, persists many years after smoking cessation. Many of the differentially 20 
methylated genes were novel genes with respect to biologic effects of smoking, and might 21 
represent therapeutic targets for prevention or treatment of tobacco-related diseases. 22 
 4 
 
Methylation at these sites could also serve as sensitive and stable biomarkers of lifetime 1 
exposure to tobacco smoke. 2 
Keywords: Epigenomic, smoking, meta-analysis, epidemiology 3 
  4 
 5 
 
Introduction 1 
Cigarette smoking is a major causal risk factor for various diseases including cancers, 2 
cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD)1, and 3 
osteoporosis2. Worldwide cessation campaigns and legislative actions have been 4 
accompanied by a reduction in the number of cigarette smokers and corresponding 5 
increases in the number of former smokers. In the US, there are more former smokers than 6 
current smokers3. Despite the decline in the prevalence of smoking in many countries, it 7 
remains the leading preventable cause of death in the world, accounting for nearly 6 8 
million deaths each year4. 9 
 10 
Even decades after cessation, cigarette smoking confers long-term risk of diseases 11 
including some cancers5, chronic obstructive pulmonary disease, and stroke6. The 12 
mechanisms for these long-term effects are not well understood. DNA methylation changes 13 
have been proposed as one possible explanation.  14 
 15 
DNA methylation appears to reflect exposure to a variety of lifestyle factors7,8, including 16 
cigarette smoking. Several studies have shown reproducible associations between tobacco 17 
smoking and altered DNA methylation at multiple cytosine-phosphate-guanine (CpG) 18 
sites9–20. Some DNA methylation sites associated with tobacco smoking have also localized 19 
to genes related to coronary heart disease10 and pulmonary disease21. Some studies have 20 
found different associated CpGs in smokers versus non-smokers13,16. Consortium-based 21 
meta-analyses have been extremely successful in identifying genetic variants associated 22 
with numerous phenotypes, but large-scale meta-analyses of genome-wide DNA 23 
 6 
 
methylation data have not yet been widely employed. It is likely that additional novel loci 1 
differentially methylated in response to cigarette smoking remain to be discovered by 2 
meta-analyzing data across larger sample sizes comprising multiple cohorts. Differentially 3 
methylated loci with respect to smoking may serve as biomarkers of lifetime smoking 4 
exposure. They may also shed light on the molecular mechanisms by which tobacco 5 
exposure predisposes to multiple diseases. 6 
 7 
A recent systematic review18 analyzed published findings across 14 epigenome-wide 8 
association studies of smoking exposure across various DNA methylation platforms of 9 
varying degrees of coverage and varying phenotypic definitions.  Among these were 12 10 
studies (comprising 4,750 subjects) that used the more comprehensive Illumina Human 11 
Methylation BeadChip 450K array (Illumina 450K), which includes and greatly expands on 12 
the coverage of the earlier 27K platform. The review compares only statistically significant 13 
published results and is not a meta-analysis which can identify signals that do not reach 14 
statistical significance in individual studies 22. 15 
 16 
In the current study, we meta-analyzed association results between DNA methylation and 17 
cigarette smoking in 15,907 individuals from 16 cohorts in the Cohorts for Heart and Aging 18 
Research in Genomic Epidemiology (CHARGE) consortium using a harmonized analysis. 19 
Methylation was measured on DNA extracted from blood samples using the Illumina 20 
Human Methylation BeadChip 450K array. In separate analyses, we compared current 21 
smokers and past smokers to non-smokers and characterized the persistence of smoking-22 
related CpG methylation associations with the duration of smoking cessation among former 23 
 7 
 
smokers. We integrated information from genome-wide association studies (GWAS) and 1 
gene expression data to gain insight into potential functional relevance of our findings for 2 
human diseases. Finally we conducted analyses to identify pathways that may explain the 3 
molecular effects of cigarette exposure on tobacco-related diseases. 4 
 Materials and Methods 5 
Study participants 6 
This study comprised a total of 15,907 participants from 16 cohorts of the Cohorts for 7 
Heart and Aging Research in Genetic Epidemiology Consortium (Supplementary Table 1). 8 
The 16 participating cohorts are ARIC, FHS Offspring, KORA F4, GOLDN, LBC 1921, LBC 9 
1936, NAS, Rotterdam, Inchianti, GTP, CHS European Ancestry (EA), CHS African Ancestry 10 
(AA), GENOA, EPIC Norfolk, EPIC, and MESA. Of these, 12,161 are of European Ancestry 11 
(EA) and 3,746 are of African Ancestry (AA). The study was approved by institutional 12 
review committees for each cohort and all participants provided written informed consent 13 
for genetic research. 14 
DNA methylation sample and measurement 15 
For most studies, methylation was measured on DNA extracted from whole blood, but 16 
some studies used CD4+ T cells or monocytes (Supplementary Table 1). In all studies, DNA 17 
was bisulfite-converted using the Zymo EZ DNA methylation kit and assayed for 18 
methylation using the Infinium HumanMethylation 450 BeadChip, which contains 485,512 19 
CpG sites. Details of genomic DNA preparation, bisulfite conversion, and methylation assay 20 
for each cohort can be found in the online Supplementary Materials. 21 
 8 
 
 1 
Raw methylated and total probe intensities were extracted using the Illumina Genome 2 
Studio methylation module. Preprocessing of the methylated signal (M) and unmethylated 3 
signal (U) was conducted using various software tools, primarily DASEN of wateRmelon23 4 
and BMIQ24, both of which are R packages. The methylation beta (β) values were defined as 5 
β = M/(M+U). Each cohort followed its own quality control protocols, removing poor 6 
quality or outlier samples and excluding low quality CpG sites (with detection p-7 
value>0.01). Each cohort evaluated batch effects and controlled for them in the analysis. 8 
Details of these processes can be found in the online Supplementary Materials. 9 
Smoking phenotype definition 10 
Self-reported cigarette smoking status was divided into three categories. Current smokers 11 
were defined as those who have smoked at least one cigarette a day within 12 months prior 12 
to the blood draw, former smokers were defined as those who had ever smoked at least 13 
one cigarette a day, but had stopped at least 12 months prior to the blood draw, and never 14 
smokers reported never having smoked. Pack years was calculated based on self-report as 15 
the average number of cigarettes per day smoked divided by 20 multiplied by the number 16 
of years of smoking, with zero assigned to never smokers. A few cohorts recorded the 17 
number of years since each former smoker had stopped smoking. 18 
Cohort specific analyses and meta-analysis 19 
Each cohort analyzed its data using at least two linear mixed effect models. Each model was 20 
run separately for each CpG site. Model 1 is as follows: 21 
 β = Smoking phenotype + Sex + Age + blood count + technical covariates,  (1) 22 
 9 
 
where blood count comprises the fractions of CD4+ T-cells, CD8+ T-cells, NK cells, 1 
monocyte, and eosinophils either measured or estimated using the Houseman et al. 2 
method25. The blood count adjustment was performed only in cohorts with whole blood 3 
and leukocyte samples. Familial relationship was also accounted for in the model when 4 
applicable (e.g., for FHS, see Supplementary Material for details). Acknowledging that each 5 
cohort may be influenced by a unique set of technical factors, we allow each cohort to 6 
choose its cohort-specific technical covariates. Model 2 added to model 1 body mass index 7 
(BMI) because it is associated with methylation at some loci, making it a potential 8 
confounder26. Only three cohorts participated in model 2 analysis: FHS, KORA, and NAS. 9 
Model 3 substituted smoking phenotypes for pack years. Only three cohorts participated in 10 
model 3 analysis: FHS, Rotterdam, and Inchianti. The pack year analysis was performed 11 
only on two subsets: current vs. never smokers and former vs. never smokers. Combining 12 
all three categories would require accurate records of time of quitting, which among the 13 
three cohorts was available for only FHS. To investigate cell type differences, we removed 14 
blood counts from Model 1 and called it Model 4. Only three cohorts participated in this 15 
analysis: FHS, KORA, and NAS. All models were run with the lme4 package27 in R28, except 16 
for FHS (See Supplementary Materials for details).  17 
 18 
Meta-analysis was performed to combine the results from all cohorts. Due to the variability 19 
of available CpG sites after quality control steps, we excluded CpG sites that were available 20 
in fewer than three cohorts. The remaining 485,381 CpG sites were then meta-analyzed 21 
with a random-effects model using the following formula: 22 
Ei = μ + si + ei,  (2) 23 
 10 
 
where Ei is the observed effect of study i, μ is the main smoking effect, si is the between-1 
study error for study i, and ei is the within-study error for study i, with both si and ei are 2 
assumed to be normally distributed. The model is fitted using the restricted maximum 3 
likelihood (REML) criterion in R’s metafor29 package. Multiple-testing adjustment on the 4 
resulting p-values was performed using the False Discovery Rate (FDR) method of 5 
Benjamini and Hochberg30. In addition, we also report results using the Bonferroni-6 
corrected threshold of 1 x 10-7 (≈ 0.05/485,381). 7 
 8 
The regression coefficient β (from meta-analysis) is interpretable as the difference in mean 9 
methylation between current and never smokers. We multiplied these by 100 to represent 10 
the percentage methylation difference where methylation ranges from 0-100%. 11 
Literature review to identify genes previously associated with smoking and 12 
methylation  13 
We used the same literature search strategy published previously31. A broad query of 14 
NCBI's PubMed literature database using medical subject heading (MeSH) terms (“((((DNA 15 
Methylation[Mesh]) OR methylation)) AND ((Smoking[Mesh]) OR smoking))”) yielded 775 16 
results when initially performed on January 8, 2015 and 789 studies when repeated to 17 
update the results on March 1, 2015. Results were reviewed by abstract to determine 18 
whether studies met inclusion criteria: 1) performed in healthy human populations, 2) 19 
agnostically examined >1,000 CpG sites at a time, 3) only cigarette exposure was 20 
considered, and 4) with public reporting of P-values and gene annotations. A total of 25 21 
publications met inclusion criteria, which is found in Supplementary Table 4 of Joubert et 22 
 11 
 
al. article31. CpG level results (P-values and gene annotations) for sites showing genome-1 
wide statistically significant associations (FDR<0.05) were extracted and resulted in 1,185 2 
genes previously associated with adult or maternal smoking. All CpGs annotated to these 3 
1,185 genes were marked as “previously found.” 4 
Gene set enrichment analysis (GSEA) 5 
Gene-Set Enrichment Analysis (GSEA)32 was performed in the website 6 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) on significant findings to 7 
determine putative functions of the CpG sites. We selected gene ontology (GO) biological 8 
process (C5-BP) and collected all categories with FDR<0.05 (up to 100 categories). 9 
 10 
Enrichment analysis for localization to different genomic features 11 
Enrichment analysis on genomic features were performed using the annotation file 12 
supplied by the Illumina (version 1.2, downloaded from manufacturer’s website, 13 
http://support.illumina.com/array/array_kits/infinium_humanmethylation450_beadchip_14 
kit/downloads.html), which contains information of CpG location relative to gene (i.e., 15 
body, first exon, 3’ UTR, 5’UTR, within 200 base pairs of Transcriptional Start Site [TSS200], 16 
and TSS1500), the relation of CpG site to a CpG island (i.e., island, northern shelf, northern 17 
shore, southern shelf, and southern shore), whether the CpG site is known to be in 18 
differentially methylated regions, and whether the CpG site is known to be an enhancer or a 19 
DNAse I Hypersensitive Site (DHS). Enrichment analysis was performed using one-sided 20 
Fisher’s exact set for each feature, using R’s fisher.test. 21 
 12 
 
Genome-wide association study (GWAS) analysis 1 
We intersected our results with SNPs having genome-wide association study (GWAS) p-2 
values≤5 x 10-8 in the NHGRI GWAS catalog (accessed November 2, 2015)33. The catalog 3 
contained 9,777 SNPs annotated to 7,075 genes associated with 865 phenotypes at p≤5x10-4 
8. To determine the genes, we looked up each significant CpG on the annotation file 5 
supplied by Illumina. Enrichment analysis was performed on a per gene basis using one-6 
sided Fisher’s exact test. 7 
 8 
For bone mineral phenotype enrichment, we included all SNPs containing terms “bone 9 
mineral density” or “osteoporosis”. For cardiovascular disease (CVD), we included all SNPs 10 
containing terms “cardiovascular disease”, “stroke”, “coronary disease”, “cardiomyopathy”, 11 
or “myocardial infarction”. For CVD risk factors, we included all SNPs containing terms 12 
“blood pressure”, “cholesterol”, “diabetes”, “obesity”, or “hypertension”. For overall cancer 13 
enrichment, we included all SNPs containing terms “cancer”, “carcinoma”, or “lymphoma”, 14 
while removing those pertaining to cancer treatment effects. For overall pulmonary 15 
phenotype enrichment, we included all SNPs containing terms “pulmonary disease”, 16 
“pulmonary function”, “emphysema”, “asthma”, or “airflow obstruction”. 17 
Analysis of persistence of methylation signals with time since quitting smoking among 18 
former smokers 19 
We examined whether smoking methylation associations were attenuated over time in the 20 
FHS cohort, which had ascertained longitudinal smoking status of over 35 years. The 21 
analysis was performed on seven dichotomous variables, indicating cessation of smoking 22 
 13 
 
for 5, 10, 15, 20, 25, and 30 years versus never smokers. For example, for five year 1 
cessation variable, those who quit smoking five years or more are marked as ones, while 2 
never smokers are marked as zeroes and current smokers are excluded. For this analysis, 3 
we used the pedigreemm package34 with the same set of covariates as in the primary 4 
analysis. Sites with p<0.002 across all seven variables were deemed to be statistically 5 
significant compared to never-smoker levels. 6 
Methylation by expression (MxE) analysis 7 
To determine transcriptomic association of each significant CpG site, we interrogated such 8 
CpG sites in the FHS gene-level methylation by expression (MxE) database, at genome-wide 9 
false discovery rate (FDR)<0.05. The MxE database was constructed from 2,262 individuals 10 
from the FHS Offspring cohort attending examination cycle eight (2005-2008) with both 11 
whole blood DNA methylation and transcriptomic data based on the Affymetrix Human 12 
Exon Array ST 1.0. Enrichment analysis was performed using a one-sided Fisher’s exact 13 
test. We defined that the methylation CpG site and the corresponding transcript are 14 
associated in cis if the location of the CpG site is within 500 kilobases of the transcript’s 15 
start location. 16 
Analysis of ethnic discrepancy between African Ancestry (AA) and European Ancestry 17 
(EA) cohorts 18 
Meta-analysis of the current versus never smoker results of EA cohorts (FHS, KORA, 19 
GOLDN, LBC 1921, LBC 1936, NAS, Rotterdam, Inchianti, EPIC, EPIC Norfolk, MESA, CHS-20 
EA) was performed separately from those of AA cohorts (ARIC, GTP, GENOA, CHS-AA). The 21 
meta-analysis procedure was identical to that discussed previously. 22 
 14 
 
 1 
Analysis of samples types for DNA extraction 2 
Meta-analysis of the results of cohorts with whole blood/buffy coat samples (FHS, KORA, 3 
LBC 1921, LBC 1936, NAS, Rotterdam, Inchianti, GTP, CHS-EA, CHS-AA, ARIC, GENOA, EPIC, 4 
and EPIC-Norfolk) was performed identically to that discussed previously. CD4+ samples in 5 
GOLDN and CD14+ samples in MESA, because they comprise single cohorts, are not meta 6 
analyzed. Correlations of results across different cell types were performed on CpG sites 7 
with FDR<0.05 in at least one cell type. 8 
Results 9 
Table 1 displays the characteristics of participants in the meta-analysis. The proportion of 10 
participants reporting current smoking ranged from 4% to 33% across the different study 11 
populations. The characteristics of the participants within each cohort are provided in 12 
Supplementary Table 1. 13 
 14 
Current versus Never Smokers 15 
In the meta-analysis of current cigarette smokers (N=2,433) versus never smokers 16 
(N=6,956), 2,623 CpGs annotated to 1,405 genes met Bonferroni significance after 17 
correction for 485,381 tests (P<1x10-7).  Based on genome-wide false discovery rate 18 
(FDR)<0.05, 18,760 CpG sites (CpGs) annotated to 7,201 genes were differentially 19 
methylated. There was a moderate inflation factor35 λ of 1.32 (Supplementary Figure 1), 20 
which is consistent with a large number of sites being impacted by smoking. Our results 21 
 15 
 
lend support many previously reported loci12,13,16,18, including CpGs annotated to AHRR, 1 
RARA, F2RL3, and LRRN3 (Supplementary Table 2). Not surprisingly, cg05575921 2 
annotated to AHRR, the top CpG identified in most prior studies of smoking, was highly 3 
significant in our meta-analysis (P=4.6x10-26; ranked 36, Supplementary Table 2) and also 4 
had the largest effect size (-18% difference in methylation) which is comparable to effect 5 
sizes in previous studies18. Of the 18,760 significant CpGs at FDR<0.05, 16,673 (annotated 6 
to 6,720 genes) have not been previously reported to be associated with cigarette smoking 7 
– these include 1,500 of the 2,623 CpGs that met Bonferroni significance. The 25 CpGs with 8 
lowest p-values for both overall and novel findings are shown in Table 2. Supplementary 9 
Table 2 provides the complete list of all CpGs that were significantly differentially 10 
methylated (FDR<0.05) in analysis of current versus never smokers. Adding body mass 11 
index (BMI) into the model did not appreciably alter the results (Supplementary Figure 2). 12 
 13 
Methylation can be either reduced or increased at CpG sites in response to smoking. For the 14 
53.2% of FDR significant CpGs with increased methylation in response to current smoking 15 
the mean percentage difference in methylation between current and never smokers was 16 
0.5%(SD=0.37%, range 0.06-7.3%). For 46.8% of CpGs with decreased methylation in 17 
response to current smoking the mean percentage difference was 0.65% (SD=0.56, range 18 
0.04-18%)  The volcano plot can be found in Supplementary Figure 3. 19 
 20 
We did not observe correlation between the number of significant CpGs and either the size 21 
of the gene or the number of exons or the coverage of the methylation platform. We 22 
performed a formal enrichment test for each of the 7,201 genes in regards to the length of 23 
 16 
 
the gene or number of exons and found only three for which associations were observed 1 
(AHRR, PRRT1, and TNF). However, given the robust findings for a specific CpG in AHRR in 2 
multiple studies in the literature9,12,14 as well as our own, and its key role in the AHR 3 
pathway which is crucial in the response to polyaromatic hydrocarbons, such as are 4 
produced by smoking36, it seems very unlikely that the AHRR findings are false positives. 5 
Likewise there is strong support in the literature for PRRT137 and TNF38. The enrichment 6 
results for methylation platform coverage also yielded the same three genes. 7 
 8 
In a subset of three cohorts (1,827 subjects), we investigated the association of the number 9 
of pack-years smoked with the 18,760 CpGs that were differentially methylated 10 
(FDR<0.05) between current versus never smokers. Significant dose responses were 11 
observed for 11,267 CpGs (60.1%) at FDR<0.05 (Supplementary Table 3).  12 
 13 
To investigate the pathways implicated by these genes, we performed a gene-set 14 
enrichment analysis39 on the annotated genes. The results suggested that cigarette smoking 15 
is associated with potential changes in numerous vital molecular processes, such as signal 16 
transduction (FDR=2.8 x 10-79), protein metabolic processes (FDR=1.2 x 10-43), and 17 
transcription pathways (FDR=8.4 x 10-31). The complete list of 99 enriched molecular 18 
processes can be found in Supplementary Table 4. 19 
 20 
Former versus Never Smokers 21 
Meta-analysis of former (N=6,518) versus never smokers (N=6,956) restricted to the 22 
18,760 CpG sites that were differentially methylated in current versus never smokers 23 
 17 
 
identified 2,568 CpGs annotated to 1,326 genes at FDR<0.05 (Supplementary Table 5). 1 
There were 285 CpGs (annotated to 149 genes) that also met Bonferroni correction (P< 2 
0.05/18760 ≈ 2.67x10-6). There was no evidence of inflation35 (λ=0.98) (Supplementary 3 
Figure 4). We also confirmed previously reported findings for CpGs annotated to AHRR, 4 
RARA, and LRRN312,13,16,18. Effect sizes of these CpGs were all weaker than in the analysis of 5 
current versus never smokers [61.2% ±15.3% weaker] for the 2,568 CpGs that remained 6 
significantly differentially methylated in former vs. never smokers compared with current 7 
vs. never smokers. Results for the top 25 CpGs are displayed in Table 3. Adding BMI to the 8 
model did not appreciably alter the results (Supplementary Figure 5). A volcano plot can be 9 
found in Supplementary Figure 6. In a subset of three cohorts (3,349 subjects), analyses 10 
using pack-years confirmed a significant dose response for 1,804 of the 2,568 CpGs (70%) 11 
annotated to 942 genes at FDR<0.05 (Supplementary Table 6).  12 
 13 
The gene-set enrichment analysis32 in the former versus never smoker analyses on all 14 
1,326 genes revealed enrichment for genes associated with protein metabolic processes 15 
(FDR=1.1 x 10-23), RNA metabolic processes (FDR=1.4 x 10-17), and transcription pathways 16 
(FDR=3.9 x 10-18) (Supplementary Table 7).  The gene-set enrichment analysis on the 942 17 
genes for which the 1,804 CpGs exhibited dose responses with pack-years also revealed 18 
similar pathways to those summarized in Supplementary Table 7, except with weaker 19 
enrichment FDR values. 20 
 21 
In 2,648 Framingham Heart Study participants with up to 30 years of prospectively 22 
collected smoking data, we examined the 2,568 CpGs that were differentially methylated in 23 
 18 
 
meta-analysis of former versus never smokers and explored their associations with time 1 
since smoking cessation. Methylation levels of most CpGs returned toward that of never-2 
smokers within five years of smoking cessation. However, 36 CpGs annotated to 19 genes, 3 
including TIAM2, PRRT1, AHRR, F2RL3, GNG12, LRRN3, APBA2, MACROD2, and PRSS23 did 4 
not return to never-smoker levels even after 30 years of smoking cessation (Figure 1, Table 5 
4). 6 
 7 
The EPIC studies included cancer cases plus non-cancer controls analyzed together, 8 
adjusting for cancer status.  The other studies were population-based samples not selected 9 
for disease status. To evaluate residual confounding by cancer status after adjustment, we 10 
repeated the meta-analysis without the EPIC studies. The effect estimates were highly 11 
correlated: Pearson ρ = 0.99 for current versus never smoking and 0.98 for former smoking 12 
versus never.   13 
 14 
Enrichment analysis for genes identified in GWAS of smoking related phenotypes 15 
To identify potential relevance of the differentially methylated genes to smoking-related 16 
phenotypes, we determined whether these genes had been associated with smoking-17 
related phenotypes in the NHGRI-EBI GWAS Catalog33 (accessed November 2, 2015). The 18 
catalog contained 9,777 SNPs annotated to 7,075 genes associated with 865 phenotypes at 19 
p≤5x10-8. Of the 7,201 genes (mapped by 18,760 CpG sites) significantly differentially 20 
methylated in current versus never smokers, we found overlap with 1,791 genes (4,187 21 
CpGs are mapped to these) associated in GWAS with 700 phenotypes (enrichment p=2.4 x 22 
10-52). We identified smoking-related traits using the 2014 US Surgeon General’s (USSG) 23 
 19 
 
report2. Enrichment results for a selection of smoking-related phenotypes including 1 
coronary heart disease (CHD) and its risk factors, various cancers, inflammatory diseases, 2 
osteoporosis, and pulmonary traits, are available in Table 5. We also performed the same 3 
enrichment analysis on the 2,568 CpGs associated with former versus never smoking 4 
status. We identified enrichment for CHD, pulmonary traits, and some cancers (Table 5). 5 
More detailed results are available in Supplementary Tables 8 and 9. Differentially 6 
methylated genes in relation to smoking status that are associated in GWAS with CHD or 7 
CHD risk factors are available in Supplementary Table 10. We also performed enrichment 8 
analyses on phenotypes that have no clear relationships to smoking, such as male pattern 9 
baldness (p=0.0888), myopia (p=0.1070), thyroid cancer (p=0.2406), and testicular germ 10 
cell tumor (p=0.3602) and did not find significant enrichment. 11 
 12 
Enrichment analysis for genomic features 13 
We examined the differentially methylated CpGs with respect to localization to different 14 
genomic regions including CpG islands, gene bodies, known differentially methylated 15 
regions, and sites identified as likely to be functionally important in the ENCODE project 16 
such as DNAse1 hypersensitivity sites and enhancers (refer to the Methods section for 17 
details). We performed this analysis separately for the CpGs related to current smoking and 18 
past smoking (Supplementary Table 11). Trends were similar for the two sets of CpGs, 19 
although the power to identify enrichment was much greater for the larger set of 18,760 20 
CpGs related to current smoking. There was no enrichment for CpG islands. In contrast, 21 
significant enrichment was observed for island shores, gene bodies, DNAse1 22 
hypersensitivity sites, and enhancers.  23 
 20 
 
 1 
Transcriptomic integration 2 
Of the 18,760 statistically significant CpG sites associated with current smoking in the 3 
meta-analysis, 1,430 were significantly associated in cis with the expression of 924 genes at 4 
FDR<0.05 (enrichment p=3.6 x 10-215, Supplementary Table 12) using whole blood samples 5 
from 2,262 Framingham Heart Study participants. Of these, 424 CpGs associated with the 6 
expression of 285 genes were replicated at FDR<0.0001 in 1,264 CD14+ samples from the 7 
Multi-Ethnic Study of Atherosclerosis (MESA)40. These genes are associated with pathways 8 
similar to those described earlier (Supplementary Table 13).  9 
 10 
Comparison between African ancestry and European ancestry 11 
Meta-analysis of the current versus never smokers in 11 cohorts with participants of 12 
European ancestry (N=6,750 subjects) yielded 10,977 CpGs annotated to 4,940 genes at 13 
FDR<0.05. Meta-analysis the results of the smaller dataset of four cohorts with African 14 
ancestry participants (N=2,639) yielded 3,945 CpGs annotated to 2,088 genes at FDR<0.05. 15 
The effect estimates of the CpGs significant in at least one ancestry (12,927 CpGs) were 16 
highly correlated in the combined group of individuals of either ancestry (Spearman 17 
ρ=0.89). The results by ancestry are shown in Supplementary Table 14.  18 
 19 
We performed the same ancestry-stratified analysis on former versus never smokers 20 
(Supplementary Table 15). Meta-analysis of the results of European ancestry participants 21 
yielded 2,045 CpG sites annotated to 1,081 genes at FDR<0.05. Meta-analysis of the results 22 
of African ancestry participants yielded 329 CpG sites annotated to 178 genes at FDR<0.05. 23 
 21 
 
The effect estimates of the union of CpGs significant in at least one ancestry (2,234 CpGs) 1 
were correlated in the combined group of individuals of either ancestry (Spearman 2 
ρ=0.75). Of note, one of CpG sites showing differential methylation in ancestry, 3 
cg00706683, mapped to gene ECEL1P2, did not return to never-smoker levels 30 years 4 
after smoking cessation (Table 4). 5 
 6 
To more directly compare results by ethnicity removing the effect of better statistical 7 
power in the larger European ancestry sample size, we performed a meta-analysis on 8 
subset of European ancestry cohorts: the Framingham Heart Study, Rotterdam Study, and 9 
KORA, such that the total number of smokers, the major determinant of power, would 10 
match that of African ancestry cohorts. In this subset, similar correlations of the effect 11 
estimates were observed as in the complete analyses suggesting that the differences in 12 
number of statistically significant CpGs are indeed due to better power in the European 13 
ancestry cohorts (Spearman ρ=0.87 and 0.79 for current versus never smokers and former 14 
versus never smokers, respectively). 15 
 16 
Cell type adjustment 17 
We adjusted our main analyses for white blood cell fractions, in studies based on either 18 
whole blood or leukocytes from the buffy coat of whole blood, either measured or using a 19 
published method25.  Reassuringly, results before and after cell type adjustment were 20 
highly comparable. The correlation of regression coefficients before and after adjustment is 21 
0.85 for the current vs. never smoker analysis (Supplementary Figure 7).  Similarly for the 22 
analysis of former versus never smokers the effect estimates were highly correlated before 23 
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and after adjustment (ρ=0.93; Supplementary Figure 8). In addition, in two cohorts we had 1 
results from specific cell fractions - CD4+ cells in GOLDN and CD14+ cells in MESA. The 2 
correlation of results between buffy coat and CD4+ or CD14+ for former versus never 3 
smokers are generally high (ρ > 0.74; Supplementary Table 16). 4 
 5 
Methylation profile across CpG sites 6 
We assessed methylation profile in FHS cohort as a representative cohort in the study. The 7 
profile of all 485,381 analyzed CpG sites can be found in Supplementary Figure 9. The 8 
profile across 18,760 CpG sites significantly associated with current vs. never smoking 9 
status can be found in Supplementary Figure 10. These plots indicate that most CpG sites 10 
with less dynamic range are largely not statistically significant in our results. 11 
Discussion 12 
We performed a genome-wide meta-analysis analysis of blood-derived DNA methylation in 13 
15,907 individuals across 16 cohorts and identified broad epigenome-wide impact of 14 
cigarette smoking, with 18,760 statistically significant CpGs (FDR<0.05) annotated to over 15 
7,000 genes, or roughly a third of known human genes. These genes in turn affect multiple 16 
molecular mechanisms and are implicated in smoking-related phenotypes and diseases. In 17 
addition to confirming previous findings from smaller studies, we detected over 16,000 18 
novel differentially methylated CpGs in response to cigarette smoking. Many of these genes 19 
have not been previously implicated in the biologic effects of tobacco exposure. The large 20 
number of genes implicated in this well powered meta-analysis might on first glance raise 21 
concerns about false positives. However, on further consideration, given the widespread 22 
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impact of smoking on disease outcomes across many organ systems and across the 1 
lifespan2, the identification of a large number of genes at genome wide significance is not 2 
surprising. In addition, our findings are robust and consistent across all 16 cohorts 3 
(Supplementary Tables 2 and 5) because we accounted for inter-study variability by using 4 
random effect meta analyses, which is conservative when heterogeneity is present41. The 5 
implicated genes are mainly involved in molecular machineries, such as transcription and 6 
translation. Furthermore, differential methylation of a subset of CpGs persisted, often for 7 
decades, following smoking cessation. 8 
 9 
We found that genes differentially methylated in relation to smoking are enriched for 10 
variants associated in GWAS with smoking–related diseases2 including,  osteoporosis, 11 
colorectal cancers, chronic obstructive pulmonary disease, pulmonary function, 12 
cardiovascular disease (CVD) and rheumatoid arthritis. We find it noteworthy that there is 13 
enrichment of smoking-associated CpGs for genes associated with rheumatoid arthritis 14 
because DNA methylation is one of the proposed molecular mechanisms underlying this 15 
disease 42. It is also interesting that the most significant association of smoking with 16 
methylation was for the gene HIVEP3 (a.k.a. Schnurri3), the mammalian homolog of the 17 
Drosophila zinc finger adapter protein Shn43.  This gene regulates bone formation, an 18 
important determinant to osteoporosis, which was one of the enriched GWAS phenotypes. 19 
 20 
When we examined time since smoking cessation, we found that the majority of the 21 
differentially methylated CpG sites observed in analysis of current versus never smokers 22 
returned to the level of never-smokers within five years of smoking cessation. This is 23 
 24 
 
consistent with the fact that risks of many smoking-related diseases revert to nonsmoking 1 
levels within this period of time. Our results also indicate that cigarette smoking induces 2 
long-lasting alterations in DNA methylation at some CpGs. While speculative, it is possible 3 
that persistent methylation changes at some loci might contribute to risks of some 4 
conditions that remain elevated after smoking cessation. 5 
 6 
In all but two of our 14 cohorts DNA was extracted from the entire circulating leukocyte 7 
population. Thus there is the possibility of confounding by the effects of smoking on 8 
differential cell counts. We attempted to adjust for cell type and found that results were 9 
generally little changed by the adjustment. 10 
 11 
Our significant results are highly enriched for CpG sites associated with the expression of 12 
nearby genes (i.e., in cis) even though a single measurement of gene expression in blood is 13 
probably subject to considerably more within-subject variability than DNA methylation,44 14 
limiting our ability to find correlations. Differential DNA methylation at many of the CpGs 15 
we identified in relation to smoking status may have a functional impact on nearby gene 16 
expression. Our analysis of genomic regions further supports the potential functional 17 
impact of our findings on gene expression. We demonstrated enrichment for sites with 18 
greater functional impact such as island shores, gene bodies, DNAse1 hypersensitivity sites, 19 
and enhancers, whereas we found no enrichment for CpG islands. These results reinforce 20 
previous findings showing that island shores, enhancers, and DHS sites are more dynamic 21 
(i.e., susceptible to methylation changes) than CpG islands45, which may be more resistant 22 
 25 
 
to abrupt changes in DNA methylation in response to environmental exposures46. Thus our 1 
results suggest that many of the smoking-associated CpG sites may have regulatory effects.  2 
 3 
While identification of changes in methylation patterns may suggest mechanisms by which 4 
exposure to tobacco smoke exerts its effects on several disease processes, DNA methylation 5 
profiles can also serve as biomarkers of exposure to tobacco smoke. Cotinine is a 6 
biomarker only of recent smoking; DNA methylation signals have the potential to serve as 7 
robust biomarkers of past smoking history14,47. Indeed, several studies have identified 8 
several of such markers10,47,48. The large number of persistently modified CpGs may be 9 
useful to develop even more robust biomarkers to objectively quantify long-term cigarette 10 
smoking exposure for prediction of risk for health outcomes in settings where smoking 11 
history is not available or is incomplete as well as to validate self-reported never smoker 12 
status.  Further, our analyses of both former and current smokers show dose-dependent 13 
effects at a number of CpGs (Supplementary Tables 3 and 7). Methylation based 14 
biomarkers could be informative for investigating dose response relationships with disease 15 
endpoints. This is useful because smokers often underreport the amount of smoking, both 16 
current and historical.  17 
 18 
It is possible that smoking related conditions or correlated exposures may contribute to 19 
some of the methylation signatures identified. However, our studies are nearly all 20 
population based studies composed of predominantly healthy individuals, not selected for 21 
smoking related disease.  Given the number, strength and robustness to replication of 22 
findings for smoking across the literature and among our diverse cohorts from various 23 
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countries the likelihood that these are confounded by other exposures or conditions 1 
related to smoking is greatly reduced.   2 
 3 
There several potential limitations to our study. First, the cross-sectional design limits our 4 
ability to study the time course of smoking effects. In addition, we analyzed methylation in 5 
DNA samples from blood, which is readily accessible. Although we demonstrated that blood 6 
derived DNA reveals a strong and robust signature of cigarette smoking exposure, studies 7 
in target tissues for smoking-related diseases (e.g., heart and lung) would be of additional 8 
interest. In addition, our analyses could not distinguish smoking’s direct effects from its 9 
indirect effects due to smoking-induced changes in cell metabolism, organ function, 10 
inflammation, or injury that could in turn influence methylation. However, this is the 11 
largest examination to date of the effects of smoking on DNA methylation with 16 studies 12 
from different countries contributing.  13 
 14 
In conclusion we identify an order of magnitude more sites differentially methylated in 15 
relation to smoking across the genome than have been previously seen. Many of these 16 
signals persist long after smoking cessation providing potential biomarkers of past 17 
smoking history. These findings may provide new insights into molecular mechanisms 18 
underlying the protean effects of smoking on human health and disease.  19 
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Tables 1 
Table 1. Participant characteristics 2 
Characteristics Current Smokers, 
N=2,433 
Former Smokers 
N=6,518 
Never Smokers 
N=6,956 
Sex (% Male) 46.3% 55.6% 31.7% 
Age (years)* 57.7 ± 7.7 64.8 ± 8.2 61.2 ± 9.7 
BMI (kg/m2)* 27.3 ± 5.4 28.7 ± 5.0 28.6 ± 5.3 
*weighted mean ± pooled standard deviation across cohorts3 
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  1 
Table 2. Most statistically significant CpG sites that were associated with current vs. never 2 
smoker status 3 
Probe ID Chr Location Gene Symbol* Coef† S.E. P FDR 
25 most significant CpG sites 
cg16145216 1 42,385,662 HIVEP3 0.0298 0.0020 6.7 x 10-48 3.3 x 10-42 
cg19406367 1 66,999,929 SGIP1 0.0175 0.0013 7 x 10-44 1.7 x 10-38 
cg05603985 1 2,161,049 SKI -0.0122 0.0009 1.8 x 10-43 2.8 x 10-38 
cg14099685 11 47,546,068 CUGBP1 -0.0124 0.0009 1.5 x 10-42 1.8 x 10-37 
cg12513616 5 177,370,977  -0.0262 0.0020 6.1 x 10-41 5.9 x 10-36 
cg03792876‡ 16 73,243  -0.0182 0.0014 7.2 x 10-38 5.9 x 10-33 
cg01097768 5 378,854 AHRR -0.0166 0.0013 6.8 x 10-35 4.7 x 10-30 
cg26856289 1 24,307,516 SFRS13A -0.0163 0.0013 8.6 x 10-35 5.2 x 10-30 
cg07954423 9 130,741,881 FAM102A -0.0134 0.0011 1.2 x 10-34 6.3 x 10-30 
cg01940273 2 233,284,934  -0.0815 0.0067 2 x 10-34 9.8 x 10-30 
cg01083131 16 67,877,413 THAP11;CENPT -0.0155 0.0013 3.7 x 10-34 1.6 x 10-29 
cg01017464 18 47,018,095 
SNORD58A; 
SNORD58B; RPL17 -0.0172 0.0014 
1.9 x 10-33 7.6 x 10-29 
cg06121808 2 113,404,678 SLC20A1 -0.0143 0.0012 2.1 x 10-32 7.9 x 10-28 
cg10062919 17 38,503,802 RARA -0.0128 0.0011 9.2 x 10-32 3.2 x 10-27 
cg20066188 22 37,678,791 CYTH4 -0.0252 0.0022 1.6 x 10-31 5.2 x 10-27 
cg04551776 5 393,366 AHRR -0.0244 0.0021 5.8 x 10-31 1.8 x 10-26 
cg11152412 15 74,927,688 EDC3 -0.0077 0.0007 1.8 x 10-30 5 x 10-26 
cg00073090 19 1,265,879  -0.0196 0.0017 4.2 x 10-30 1.1 x 10-25 
cg11902777 5 368,843 AHRR -0.0201 0.0018 9.1 x 10-30 2.3 x 10-25 
cg25212453 17 1,509,953 SLC43A2 -0.0101 0.0009 1.4 x 10-29 3.5 x 10-25 
cg04956244 17 38,511,592 RARA 0.0122 0.0011 1.5 x 10-29 3.5 x 10-25 
cg13951797 16 2,204,381 TRAF7 -0.0153 0.0014 1.6 x 10-29 3.5 x 10-25 
cg11028075 10 97,200,911 SORBS1 0.0175 0.0016 1.7 x 10-29 3.6 x 10-25 
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cg11700584† 14 50,088,544 RPL36AL;MGAT2 -0.0151 0.0013 3.4 x 10-29 6.8 x 10-25 
cg11263997 11 70,257,280 CTTN 0.0050 0.0005 4.3 x 10-29 8.4 x 10-25 
25 most significant novel CpG sites 
cg11700584 14 50,088,544 RPL36AL; MGAT2 -0.0151 0.0013 3.4 x 10-29 6.8 x 10-25 
cg22417733 6 153,303,409 FBXO5 -0.0171 0.0015 1.5 x 10-28 2.7 x 10-24 
cg08118908 16 15,787,920 NDE1 0.0053 0.0005 5.4 x 10-26 7.1 x 10-22 
cg14003265 9 139,796,499 TRAF2 -0.0106 0.0010 3.2 x 10-25 3.7 x 10-21 
cg02556393 3 168,866,705 MECOM -0.0162 0.0016 2.8 x 10-24 2.6 x 10-20 
cg01218206 11 116,933,977 SIK3 -0.0150 0.0015 3.1 x 10-23 2.5 x 10-19 
cg04987734 14 103,415,873 CDC42BPB 0.0149 0.0015 9.0 x 10-23 6.8 x 10-19 
cg27118035 16 31,891,978 ZNF267 0.0136 0.0014 2.4 x 10-22 1.7 x 10-18 
cg18450254 3 64,200,005 PRICKLE2 0.0120 0.0013 2.3 x 10-21 1.3 x 10-17 
cg06753787 2 220,074,208 ZFAND2B 0.0063 0.0007 3.2 x 10-21 1.8 x 10-17 
cg18158306 12 133,135,032 FBRSL1 0.0102 0.0011 6.2 x 10-21 3.2 x 10-17 
cg19093370 17 17,110,180 PLD6 0.0198 0.0021 8.7 x 10-21 4.4 x 10-17 
cg09182189 1 1,709,203 NADK -0.0104 0.0011 2.0 x 10-20 9.2 x 10-17 
cg18369990 2 112,941,244 FBLN7 0.0116 0.0013 2.3 x 10-20 1.1 x 10-16 
cg24578857 17 17,110,207 PLD6 0.0200 0.0022 3.1 x 10-20 1.4 x 10-16 
cg20408402 10 72,362,452 PRF1 0.0085 0.0009 7.6 x 10-20 3.1 x 10-16 
cg04673446 22 39,879,951 MGAT3 0.0060 0.0007 2.0 x 10-19 8.0 x 10-16 
cg06803614 1 40,133,581 NT5C1A -0.0088 0.0010 2.1 x 10-19 8.3 x 10-16 
cg16274678 1 154,127,952 TPM3; NUP210L -0.0152 0.0017 2.9 x 10-19 1.1 x 10-15 
cg07286341 5 176,923,805 PDLIM7 -0.0077 0.0009 3.4 x 10-19 1.3 x 10-15 
cg20674424 3 186,503,527 MIR1248; EIF4A2; 
SNORA81 
-0.0091 0.0010 4.2 x 10-19 1.5 x 10-15 
cg02279625 15 78,384,520 SH2D7 0.0105 0.0012 4.8 x 10-19 1.7 x 10-15 
cg03485667 16 75,143,200 ZNRF1 -0.0168 0.0019 5.0 x 10-19 1.8 x 10-15 
cg03531211 6 32,920,102 HLA-DMA -0.0108 0.0012 7.5 x 10-19 2.5 x 10-15 
cg09940677 14 103,415,458 CDC42BPB 0.0081 0.0009 1.0 x 10-18 3.2 x 10-15 
*CpG sites without gene names are intergenic. These are all included in all the analyses. 1 
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†Coef stands for regression coefficients 1 
‡Not previously discovered by other studies 2 
 3 
  4 
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Table 3. Twenty-five most statistically significant CpG sites that were associated with 1 
former vs. never smoker status 2 
Probe ID Chr Location Gene Symbol* Coef† S.E. P FDR 
cg01940273 2 233,284,934  -0.0234 0.0013 9.6 x 10-73 1.8 x 10-68 
cg25189904 1 68,299,493 GNG12 -0.0283 0.0021 3.5 x 10-40 3.3 x 10-36 
cg12803068 7 45,002,919 MYO1G 0.0191 0.0017 9.3 x 10-31 5.8 x 10-27 
cg19572487 17 38,476,024 RARA -0.0159 0.0014 2.2 x 10-30 1.0 x 10-26 
cg11554391 5 321,320 AHRR -0.0091 0.0008 1.0 x 10-28 3.9 x 10-25 
cg05951221 2 233,284,402  -0.0396 0.0036 1.1 x 10-27 3.2 x 10-24 
cg23771366 11 86,510,998 PRSS23 -0.0167 0.0015 1.2 x 10-27 3.2 x 10-24 
cg26764244 1 68,299,511 GNG12 -0.0119 0.0011 2.3 x 10-27 5.4 x 10-24 
cg05575921 5 373,378 AHRR -0.0406 0.0038 8.2 x 10-27 1.7 x 10-23 
cg11660018 11 86,510,915 PRSS23 -0.0157 0.0015 4.3 x 10-26 8.1 x 10-23 
cg21566642 2 233,284,661  -0.0434 0.0041 1.0 x 10-25 1.7 x 10-22 
cg11902777 5 368,843 AHRR -0.0063 0.0006 2.8 x 10-25 4.3 x 10-22 
cg26850624 5 429,559 AHRR 0.0118 0.0011 3.1 x 10-25 4.4 x 10-22 
cg03636183 19 17,000,585 F2RL3 -0.0267 0.0026 8.9 x 10-25 1.2 x 10-21 
cg15693572 3 22,412,385  0.0190 0.0019 1.5 x 10-23 1.9 x 10-20 
cg17924476 5 323,794 AHRR 0.0148 0.0016 4.0 x 10-20 4.7 x 10-17 
cg12513616 5 177,370,977  -0.0072 0.0008 2.4 x 10-19 2.7 x 10-16 
cg07339236 20 50,312,490 ATP9A -0.0062 0.0007 1.4 x 10-18 1.4 x 10-15 
cg06126421 6 30,720,080  -0.0365 0.0042 3.0 x 10-18 3.0 x 10-15 
cg14624207 11 68,142,198 LRP5 -0.0070 0.0008 5.0 x 10-18 4.7 x 10-15 
cg00706683 2 233,251,030 ECEL1P2 0.0101 0.0012 1.4 x 10-17 1.2 x 10-14 
cg23351584 11 86,512,100 PRSS23 -0.0048 0.0006 7.0 x 10-17 6.0 x 10-14 
cg02583484 12 54,677,008 HNRNPA1 -0.0062 0.0008 1.0 x 10-15 8.5 x 10-13 
cg05302489 6 31,760,426 VARS 0.0079 0.0010 2.5 x 10-15 2.0 x 10-12 
cg01442064 4 5,713,450 EVC -0.0055 0.0007 3.3 x 10-15 2.4 x 10-12 
*CpG sites without gene names are intergenic. These are all included in all the analyses. 3 
 38 
 
†Coef stands for regression coefficients 1 
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Table 4. The top 36 most statistically significant CpG sites that did not return to never-1 
smoker levels 30 years after smoking cessation in the Framingham Heart Study (N=2,648) 2 
Probe ID Chr Location Gene Symbol P 
cg05951221 2 233284402  3.2 x 10-15 
cg06644428 2 233284112  1.2 x 10-14 
cg05575921 5 373378 AHRR 6.5 x 10-14 
cg21566642 2 233284661  8.6 x 10-10 
cg03636183 19 17000585 F2RL3 5.7 x 10-7 
cg06126421 6 30720080  1.3 x 10-6 
cg01940273 2 233284934  1.9 x 10-6 
cg23771366 11 86510998 PRSS23 3.1 x 10-6 
cg17272563 6 32116548 PRRT1 4.4 x 10-6 
cg23916896 5 368804 AHRR 1.3 x 10-5 
cg11660018 11 86510915 PRSS23 1.3 x 10-5 
cg08118908 16 15787920 NDE1 3.0 x 10-5 
cg13937905 12 53612551 RARG 1.5 x 10-4 
cg24172324 2 232258363  1.7 x 10-4 
cg10780313 6 33501379  2.0 x 10-4 
cg14027333 6 32116317 PRRT1 2.1 x 10-4 
cg11245297 19 8117898 CCL25 2.1 x 10-4 
cg01692968 9 108005349  3.1 x 10-4 
cg00706683 2 233251030 ECEL1P2 3.4 x 10-4 
cg25317941 2 233351153 ECEL1 4.0 x 10-4 
cg25189904 1 68299493 GNG12 4.0 x 10-4 
cg14179389 1 92947961 GFI1 4.7 x 10-4 
cg13641317 3 127255552  4.9 x 10-4 
cg19847577 15 29213748 APBA2 5.1 x 10-4 
cg14239618 7 110281356  5.8 x 10-4 
cg25955180 6 32116538 PRRT1 6.3 x 10-4 
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cg00774149 3 52255721 TLR9 6.4 x 10-4 
cg21351392 6 161607487 AGPAT4 7.1 x 10-4 
cg11902777 5 368843 AHRR 7.6 x 10-4 
cg07251887 17 73641809 LOC100130933; RECQL5 7.7 x 10-4 
cg19382157 7 2124566 MAD1L1 8.9 x 10-4 
cg19925780 1 101509557  1.1 x 10-3 
cg03679544 6 155537972 TIAM2 1.1 x 10-3 
cg08559712 20 16030674 MACROD2 1.3 x 10-3 
cg09837977 7 110731201 LRRN3; IMMP2L 1.3 x 10-3 
cg00931843 6 155442993 TIAM2 1.4 x 10-3 
*CpG sites without gene names are intergenic. These are all included in all the analyses.  1 
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Table 5. Enrichment of CpGs for genome-wide association study (GWAS) phenotypes that 1 
are regarded as causally related to cigarette smoking2 2 
GWAS Phenotype Enrichment p-value 
Current vs. never smoking 
Coronary heart disease (CHD) and Stroke 0.0028 
    Ischemic stroke 0.0095 
CHD risk factors 1.2 x 10-12 
    Blood pressure / hypertension 8.1 x 10-6 
        Diastolic blood pressure 6.1 x 10-5 
        Systolic blood pressure 0.0008 
        Hypertension 0.0150 
    Lipids 2.9 x 10-5 
        High density lipoprotein (HDL) 0.0009 
    Type 2 diabetes 0.0106 
Rheumatoid arthritis (RA) 2.9 x 10-5 
Bone mineral density (BMD) and osteoporosis 0.0467 
All pulmonary traits 2.8 x 10-6 
    All chronic obstructive pulmonary disease (COPD) 0.0295 
        Moderate to severe COPD 0.0156 
    Pulmonary function 0.0044 
Crohn’s Disease 9.5 x 10-7 
Primary biliary cirrhosis 3.4 x 10-6 
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Inflammation bowel disease 3.5 x 10-5 
Ulcerative colitis 9.8 x 10-5 
All cancer 8.0 x 10-15 
    Lung adenocarcinoma 0.0015 
    Colorectal cancer 0.0014 
Former vs. never smoking 
CHD risk factors 7.6 x 10-5 
    Blood pressure / hypertension 5.8 x 10-5 
        Diastolic blood pressure 0.0021 
        Systolic blood pressure 0.0002 
        Hypertension 0.0023 
Rheumatoid arthritis (RA) 6.3 x 10-5 
All pulmonary traits 0.0217 
Inflammation bowel disease 5.2 x 10-6 
Crohn’s Disease 0.0064 
All cancer 7.8 x 10-6 
 1 
  2 
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Figure 1 
 2 
Figure 1. Trajectories of CpG sites that did not return to never-smoker levels within 30 3 
years after cessation. 4 
